The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)

IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes t...

Full description

Bibliographic Details
Main Authors: Wanhai Ke, Li Zhang, Yan Dai
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Interleukin‐6
non‐small cell lung cancer
immune related adverse events
Online Access:https://doi.org/10.1111/1759-7714.13341
id doaj-09864b9884dc4dfdbc5839b54b1ec7a8
record_format Article
spelling doaj-09864b9884dc4dfdbc5839b54b1ec7a82020-11-25T02:08:46ZengWileyThoracic Cancer1759-77061759-77142020-04-0111483583910.1111/1759-7714.13341The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)Wanhai Ke0Li Zhang1Yan Dai2Arrhythmia Center, Fuwai Hospital, Peking Union Medical College Chinese Academy of Medical Sciences Beijing ChinaRespiratory Medicine Department, Peking Union Medical College Hospital, Peking Union Medical College Chinese Academy of Medical Sciences Beijing ChinaArrhythmia Center, Fuwai Hospital, Peking Union Medical College Chinese Academy of Medical Sciences Beijing ChinaIL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes the diagnostic and prognostic value of IL‐6 level. Anti‐IL‐6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune‐related adverse events (irAEs) in the future. Therefore, IL‐6 may be a therapeutic target for the treatment of NSCLC.https://doi.org/10.1111/1759-7714.13341Interleukin‐6non‐small cell lung cancerimmune related adverse events
collection DOAJ
language English
format Article
sources DOAJ
author Wanhai Ke
Li Zhang
Yan Dai
spellingShingle Wanhai Ke
Li Zhang
Yan Dai
The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
Thoracic Cancer
Interleukin‐6
non‐small cell lung cancer
immune related adverse events
author_facet Wanhai Ke
Li Zhang
Yan Dai
author_sort Wanhai Ke
title The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_short The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_full The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_fullStr The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_full_unstemmed The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_sort role of il‐6 in immunotherapy of non‐small cell lung cancer (nsclc) with immune‐related adverse events (iraes)
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2020-04-01
description IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes the diagnostic and prognostic value of IL‐6 level. Anti‐IL‐6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune‐related adverse events (irAEs) in the future. Therefore, IL‐6 may be a therapeutic target for the treatment of NSCLC.
topic Interleukin‐6
non‐small cell lung cancer
immune related adverse events
url https://doi.org/10.1111/1759-7714.13341
work_keys_str_mv AT wanhaike theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT lizhang theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT yandai theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT wanhaike roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT lizhang roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT yandai roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
_version_ 1724925535610470400

Similar Items